PharmaNutra signs an agreement with Trigen Pharma International

Published: 15 January 2019 09:35

Trigen Pharma International will be distributing SiderAL® branded products in Pakistan, marking a significant new step forward in the process of international expansion of PharmaNutra Group.

 

PharmaNutra is pleased to announce the signing of an agreement with Trigen Pharma International, a Pakistani pharmaceutical giant founded in 1994 that manufactures and sells leading-edge medical and nutraceutical devices, for the distribution in Pakistan of its products with Sucrosomial Iron®, the innovative patent that has earned PharmaNutra Group a leadership position in the production of iron-based nutritional supplements.

 

Trigen Pharma International will be distributing the following products in Pakistan on behalf of PharmaNutra: SiderAL® Forte Int, SiderAL® Folico 30 and CardioSiderAL®; for Junia Pharma, it will be distributing SiderAL® Oro and SiderAL® Gocce, both in the INT version.

 

With a population of over 200 million, Pakistan is the sixth most densely populated country in the world, in which the pharmaceutical sector is one of the most rapidly expanding, with a growth rate of around 15% a year (source: Infomercatiesteri.it – Italian Foreign Ministry Report – Italian Embassy Pakistan 2016). For this reason, Pakistan is an extremely attractive market for the spread of products featuring Sucrosomial Iron®, a technology that is continuing to receive praise from authoritative members of the international scientific community, supported by important results in terms of sales.

 

Andrea Lacorte, President of PharmaNutra, explained: “This agreement with Trigen Pharma International will allow us to introduce our Sucrosomial Iron® into a large market for which we have high expectations. The prestigious international standing of our partner will allow us to get off to the best possible start. The most important aspect of this agreement is that Trigen Pharma will be distributing PharmaNutra brand products, something that is not to be taken for granted in a market that places such strong restrictions on the entrance of finished products”.